Was the Enalapril Dose Too Low in the PARADIGM-HF Trial?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Was the Enalapril Dose Too Low in the PARADIGM-HF Trial?

Published:2018-07 Issue:4 Volume:26 Page:196-200
ISSN:1061-5377
Container-title:Cardiology in Review
language:en
Short-container-title:

Author:

Bernardez-Pereira Sabrina,Ramires Felix José Alvares,de Melo Rachel Figueiredo Tavares,Pereira-Barretto Antonio Carlos

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Reference26 articles.

1. Re-hospitalizações e morte por insuficiência cardíaca. Índices ainda alarmantes.;Pereira-Barretto;Arq Bras Cardiol,2008

2. The medical and socioeconomic burden of heart failure: a comparative delineation with cancer.;Farmakis;Int J Cardiol,2016

3. Angiotensin-neprilysin inhibition versus enalapril in heart failure.;McMurray;N Engl J Med,2014

4. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.;McMurray;Eur Heart J,2012

5. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.;Yancy;J Am Coll Cardiol,2016

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sacubitril/valsartan compared to equivalent/sub-equivalent dose angiotensin receptor blocker or angiotensin-converting enzyme inhibitor in heart failure with reduced ejection fraction: a meta-analysis of randomized trials;European Journal of Clinical Pharmacology;2024-04-10

2. Is Sacubitril/Valsartan a Superior Agent in Heart Failure With Reduced Ejection Fraction? A Review of Randomized Comparative Trials;Hospital Pharmacy;2023-12-06

3. Real-world use patterns of angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan) among patients with heart failure within a large integrated health system;Journal of Managed Care & Specialty Pharmacy;2022-10

4. New and developing pharmacotherapies for hypertension;Expert Review of Cardiovascular Therapy;2022-08-03

5. Beneficial and harmful effects of sacubitril/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis;Open Heart;2020-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3